Swiss Life Asset Management Ltd lifted its stake in shares of Quest Diagnostics Incorporated (NYSE:DGX – Free Report) by 132.8% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 43,338 shares of the medical research company’s stock after buying an additional 24,722 shares during the period. Swiss Life Asset Management Ltd’s holdings in Quest Diagnostics were worth $7,520,000 at the end of the most recent quarter.
Other institutional investors have also bought and sold shares of the company. Vanguard Group Inc. lifted its stake in Quest Diagnostics by 1.0% during the 4th quarter. Vanguard Group Inc. now owns 14,392,082 shares of the medical research company’s stock valued at $2,497,458,000 after acquiring an additional 140,450 shares in the last quarter. State Street Corp grew its stake in shares of Quest Diagnostics by 0.8% in the 3rd quarter. State Street Corp now owns 5,223,930 shares of the medical research company’s stock worth $995,577,000 after acquiring an additional 38,931 shares in the last quarter. Boston Partners raised its holdings in shares of Quest Diagnostics by 32.8% in the third quarter. Boston Partners now owns 4,036,881 shares of the medical research company’s stock valued at $767,978,000 after purchasing an additional 997,033 shares during the last quarter. Dimensional Fund Advisors LP lifted its position in shares of Quest Diagnostics by 0.3% during the third quarter. Dimensional Fund Advisors LP now owns 1,907,510 shares of the medical research company’s stock valued at $363,509,000 after purchasing an additional 6,155 shares in the last quarter. Finally, Invesco Ltd. boosted its holdings in Quest Diagnostics by 1.8% during the third quarter. Invesco Ltd. now owns 1,688,769 shares of the medical research company’s stock worth $321,846,000 after purchasing an additional 30,418 shares during the last quarter. Institutional investors own 88.06% of the company’s stock.
Analyst Ratings Changes
Several equities research analysts have commented on the stock. Citigroup increased their price objective on shares of Quest Diagnostics from $190.00 to $215.00 and gave the company a “neutral” rating in a research note on Tuesday, February 10th. Wall Street Zen upgraded Quest Diagnostics from a “hold” rating to a “buy” rating in a research note on Saturday, April 25th. Jefferies Financial Group reaffirmed a “buy” rating and issued a $225.00 target price on shares of Quest Diagnostics in a report on Tuesday, April 21st. Weiss Ratings raised Quest Diagnostics from a “buy (b)” rating to a “buy (b+)” rating in a research report on Monday, May 4th. Finally, Truist Financial lifted their price target on Quest Diagnostics from $220.00 to $225.00 and gave the stock a “hold” rating in a report on Wednesday, April 22nd. Seven analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $216.58.
Quest Diagnostics Stock Performance
NYSE DGX opened at $190.74 on Thursday. The company has a market capitalization of $21.11 billion, a PE ratio of 21.08, a price-to-earnings-growth ratio of 2.26 and a beta of 0.60. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.08 and a current ratio of 1.18. Quest Diagnostics Incorporated has a 52-week low of $164.65 and a 52-week high of $213.50. The company has a 50-day simple moving average of $196.56 and a 200 day simple moving average of $189.91.
Quest Diagnostics (NYSE:DGX – Get Free Report) last released its earnings results on Tuesday, April 21st. The medical research company reported $2.50 earnings per share for the quarter, beating analysts’ consensus estimates of $2.37 by $0.13. Quest Diagnostics had a net margin of 9.07% and a return on equity of 15.60%. The firm had revenue of $2.90 billion during the quarter, compared to the consensus estimate of $2.83 billion. During the same period in the prior year, the firm earned $1.94 EPS. The company’s revenue was up 9.2% compared to the same quarter last year. Quest Diagnostics has set its FY 2026 guidance at 10.630-10.830 EPS. On average, research analysts predict that Quest Diagnostics Incorporated will post 10.73 EPS for the current year.
Quest Diagnostics declared that its board has authorized a stock repurchase program on Tuesday, February 10th that allows the company to repurchase $1.00 billion in shares. This repurchase authorization allows the medical research company to buy up to 4.7% of its stock through open market purchases. Stock repurchase programs are usually a sign that the company’s leadership believes its shares are undervalued.
Insider Transactions at Quest Diagnostics
In other news, SVP Karthik Kuppusamy sold 2,628 shares of the company’s stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $204.86, for a total transaction of $538,372.08. Following the transaction, the senior vice president owned 13,441 shares of the company’s stock, valued at $2,753,523.26. This represents a 16.35% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Catherine T. Doherty sold 5,558 shares of Quest Diagnostics stock in a transaction dated Thursday, March 5th. The stock was sold at an average price of $206.21, for a total value of $1,146,115.18. Following the completion of the sale, the executive vice president directly owned 67,122 shares of the company’s stock, valued at approximately $13,841,227.62. This trade represents a 7.65% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 18,421 shares of company stock worth $3,790,214 in the last ninety days. Company insiders own 0.88% of the company’s stock.
Quest Diagnostics Profile
Quest Diagnostics (NYSE: DGX) is a leading provider of diagnostic information services that supports clinical decision-making for patients, physicians and healthcare organizations. The company operates a network of clinical laboratories and patient service centers that perform a broad range of laboratory tests and diagnostic assays used in routine care, disease diagnosis, monitoring and screening.
Its services span core clinical laboratory testing, anatomic pathology, molecular and genomic diagnostics, infectious disease testing and toxicology.
Featured Stories
- Five stocks we like better than Quest Diagnostics
- D-Wave Earnings Looked Weak, But Investors May Be Missing This
- Nebius Upside Expands as AI Feedback Loop Intensifies
- Insider Trades: Okta and Abbott See Buys, Micron Insiders Sell
- Plug Power Flips The Switch On Profitability
Want to see what other hedge funds are holding DGX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Quest Diagnostics Incorporated (NYSE:DGX – Free Report).
Receive News & Ratings for Quest Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.
